SCHEMBL16468005

SCHEMBL16468005

Cc1cccc(Nc2ccc(O[Si](C)(C)C(C)(C)C)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.53
CCR4 P51679 1/20 0.43
NFKB1 P19838 1/20 0.41
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
PREP P48147 1/20 0.39
KCNH3 Q9ULD8 1/20 0.39
HTT P42858 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
CA12 O43570 3/20 0.38
CA1 P00915 3/20 0.38
CA9 Q16790 3/20 0.38
ADORA2A P29274 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9479693 0.84 ALDH1A1 (0.46) NPSR1PREPHTTMEN1KMT2A
SCHEMBL16411847 0.84 ALDH1A1 (0.46) NPSR1PREPHTTMEN1KMT2A
SCHEMBL6155918 0.84 PREP (0.44) NPSR1PREPMEN1KMT2ACA12
SCHEMBL16467953 0.84 MEN1 (0.55) NPSR1AKR1C3AKR1C2HTTMEN1
SCHEMBL16467837 0.84 HPGD (0.44) AKR1C3AKR1C2MEN1KMT2AKDR
SCHEMBL15152501 0.84 RAPGEF4 (0.41) NPSR1MEN1KMT2ACA12CA1
SCHEMBL16468141 0.84 GAA (0.46) NPSR1PREPHTTMEN1KMT2A
SCHEMBL9479203 0.82 MEN1 (0.46) NPSR1HTTMEN1KMT2ACA12
SCHEMBL17782675 0.82 KDR (0.45) NPSR1AKR1C3HTTMEN1KMT2A
SCHEMBL16468109 0.82 APP (0.53) AKR1C3AKR1C2MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10258626-B2 Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATORIES SERVIER (FR) 2019-04-16 US disclosed
US-20170151251-A1 INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2017-06-01 US disclosed
US-9603854-B2 Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2017-03-28 US disclosed
EP-2807159-B1 NEW INDOLIZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF CANCER SERVIER LAB (FR) 2016-11-23 EP disclosed
US-20150313911-A1 INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM VERNALIS (R&D) LTD (GB) 2015-11-05 US disclosed
US-9120791-B2 Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2015-09-01 US disclosed
US-20150051189-A1 INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM VERNALIS (R&D) LTD (GB) 2015-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150313911-A1 INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM IDO1, IDO2, API5 NPSR1 1000/4885CCR4 612/4885NFKB1 69/4885
US-10258626-B2 Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them IDO1, IDO2, API5 NPSR1 1000/4885CCR4 612/4885NFKB1 69/4885
US-20150051189-A1 INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM IDO1, IDO2, API5 NPSR1 1000/4885CCR4 612/4885NFKB1 69/4885
US-20170151251-A1 INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM IDO1, IDO2, API5 NPSR1 1000/4885CCR4 612/4885NFKB1 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.